1201187-44-1 Usage
Description
tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate is a synthetic reagent used in the preparation of tricyclic heterocycles, which are compounds with potential kinase inhibitory activity. tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate plays a crucial role in the development of novel nitrogen-containing tricyclic compounds that can be utilized as kinase inhibitors for various therapeutic applications.
Uses
Used in Pharmaceutical Industry:
tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate is used as a synthetic reagent for the preparation of tricyclic heterocycles with kinase inhibitory activity. These tricyclic compounds are being developed as potential therapeutic agents for treating immunological and oncological conditions.
Used in Research and Development:
In the field of research and development, tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate serves as a valuable compound for the synthesis of novel nitrogen-containing tricyclic compounds. These compounds are being investigated for their potential as kinase inhibitors, which could have significant implications in the treatment of various diseases, particularly those related to the immune system and cancer.
Used in Drug Design and Synthesis:
tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate is utilized as a key intermediate in the design and synthesis of new drugs targeting specific kinases. By inhibiting the activity of these enzymes, these novel compounds may help in the development of more effective treatments for a range of immunological and oncological conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1201187-44-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,1,1,8 and 7 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1201187-44:
(9*1)+(8*2)+(7*0)+(6*1)+(5*1)+(4*8)+(3*7)+(2*4)+(1*4)=101
101 % 10 = 1
So 1201187-44-1 is a valid CAS Registry Number.
1201187-44-1Relevant articles and documents
Development of a Scalable Enantioselective Synthesis of JAK Inhibitor Upadacitinib
Bhagavatula, Lakshmi,Christesen, Alan,Dunn, Travis B.,Ickes, Andrew,Kotecki, Brian J.,Marek, James C.,Morrill, Westin H.,Moschetta, Eric,Mulhern, Mathew,Rasmussen, Michael,Reynolds, Troy,Rozema, Michael J.,Yu, Su
, (2021/10/21)
Process development of a six-stage synthesis of upadacitinib, a JAK1 inhibitor, is described. It is highlighted by an enantioselective and diastereoselective hydrogenation of a tetrasubstituted olefin to set the two pyrrolidine stereocenters. Preparation of the main fragments and strategies to link them together, optimization of the imidazole cyclization, and in-depth understanding of the formation of the urea moiety at the final stage are discussed.
Influenza virus replication inhibitors and uses thereof (by machine translation)
-
, (2019/10/01)
The invention provides a compound as an influenza virus replication inhibitor, a method for preparing the same, a pharmaceutical composition containing the compound and application. (by machine translation)
Preparation of (5 - tosyl - 555H-pyrrolo [2, 3 - b] pyrazine -2 -yl) carbamic acid tert-butyl ester (by machine translation)
-
Paragraph 0016-0017, (2019/09/14)
The present invention relates to (5 - tosyl - 555H-pyrrolo [2. The preparation method comprises the following steps: 3 - b,2 - diamine as a starting raw material, synthesizing (-2, 5 -] pyrazino 5 -yl) carbamic acid tert-butyl ester through a series of re
